Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11847945 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL11851404 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL8967917 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL664937 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL5857163 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| Laurocapram SCHEMBL23347 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL10427239 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL10427195 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| Laurocapram SCHEMBL2150444 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL11855053 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-5527797-A | IONTOPHORESIS | MACROCHEM CORPORATION (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0311632-B1 | SURFACE ACTIVE LACTAMS | ISP INVESTMENTS INC (US) | 1996-05-29 | — | — | EP | disclosed |
| EP-0552879-A1 | Improved iontophoretic administration of drugs | MACROCHEM CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| EP-0247900-B1 | TOPICAL METHOTREXATE PREPARATION FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-12-18 | — | — | EP | disclosed |
| EP-0311632-A4 | SURFACE ACTIVE LACTAMS | — | 1990-12-27 | — | — | EP | disclosed |
| EP-0258434-A4 | COMPOSITION COMPRISING AN OXYGENATED CHOLESTEROL. | JAVITT NORMAN B (US) | 1989-11-07 | — | — | EP | disclosed |
| EP-0311632-A1 | SURFACE ACTIVE LACTAMS. | GAF CORP (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4753958-A | PSORIASIS | UNIVERSITY OF CAL (US) | 1988-06-28 | — | — | US | disclosed |
| US-4743597-A | ANTIINFLAMMATORY, PSORIASIS | WHITBY RESEARCH, INC. | 1988-05-10 | — | — | US | disclosed |
| EP-0247900-A1 | Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1987-12-02 | — | — | EP | disclosed |
| WO-1987004346-A1 | COMPOSITION COMPRISING AN OXYGENATED CHOLESTEROL AND USE THEREOF FOR TOPICAL TREATMENT OF DISEASES | JAVITT NORMAN B | 1987-07-30 | — | — | WO | disclosed |
| EP-0077078-B1 | METHOD FOR IMPROVED PLANT PEST CONTROL | Whitby Research Incorporated (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4525199-A | Method of improved pest control | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1985-06-25 | — | — | US | disclosed |
| US-4444762-A | Vehicle composition containing 1-substituted azacyclopentan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
| US-4424210-A | Vehicle composition containing 1-substituted azacycloalkan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4423040-A | Vehicle composition containing 1-substituted azacyclohexan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4415563-A | TOPICAL APPLICATION OF MEDICINE; COSMETICS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0077078-A1 | Method for improved plant pest control | Whitby Research Incorporated (US) | 1983-04-20 | — | — | EP | disclosed |
| US-4316893-A | USED FOR TOPICAL APPLICATION WITH A PHYSIOLOGICALLY ACTIVE AGENT | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ALOX5 34/4885GAA 2993/4885FAAH 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.